Byetta, Dibenzyline and 15 Other Drugs Are Off the Market. FDA Says Safety Was Not the Reason.

The Food and Drug Administration has determined that 17 drug products no longer sold in the United States, among them the exenatide pen Byetta, the phenoxybenzamine capsule Dibenzyline and the 20 mg tafamidis capsule Vyndaqel, were not withdrawn from sale for reasons of safety or effectiveness. The finding appeared in a Federal Register notice published Nov. 13, 2026.

The determination lets generic versions that reference those products stay on the market and lets FDA keep approving new ones. To see what is actually left for prescribers, we checked each of the 17 against FDA's Drugs@FDA database on Nov. 13. Fourteen have at least one other approved product with the same ingredient, dosage form and strength listed as marketed. Three do not: inhaled ribavirin, twice-daily exenatide and 100 mg etoposide capsules.

What does the determination do?

Under 21 CFR 314.161, FDA must decide whether a listed drug left the market for safety or effectiveness reasons when it is voluntarily withdrawn and generics referencing it have been approved, or before a new generic referencing it can be approved. A finding that it did not leave for those reasons keeps the product in the Discontinued Drug Product List section of the Orange Book, rather than starting proceedings that could pull the generics too. The notice says only that FDA "has become aware" the products are no longer marketed. It gives no reason for any company's decision.

The list runs across specialties: two alpha-blockers, an antipsychotic depot injection, an inhaled antiviral, an oral chemotherapy capsule, an angiotensin-converting enzyme inhibitor, a urea cycle drug, two sleep aids, a vitamin D analog, an incretin, a nebulized bronchodilator, a steroid injection, a high-strength fluoxetine tablet, an intravenous antifungal, a transthyretin stabilizer and an angiography dye.

What is still on the market?

The table shows our count for each product. A marketed listing in Drugs@FDA means a company reports selling the product. It does not guarantee that a wholesaler or a local pharmacy has it.

Two single-alternative rows deserve a note. Tafamidis meglumine 20 mg now has one generic listed as marketed, Aurobindo Pharma's, whose application Drugs@FDA shows as approved Nov. 6, 2026. Pfizer's 61 mg tafamidis capsule, Vyndamax, remains listed as marketed. For 25 percent fluorescein, Zydus Lifesciences is the only marketed source at that strength, and the 10 percent concentration has several.

For 14 of these products the change is a new name on the pharmacy label. For three, it is a prescribing decision.

Where are the gaps?

Exenatide is the largest. Byetta is gone, and the only approved generic, Amneal's exenatide pen, approved Nov. 19, 2024, is also marked discontinued in Drugs@FDA. So are both extended-release versions, Bydureon and Bydureon BCise. Drugs@FDA still marks Byetta as a prescription product under a second application number, NDA 021919, a 2009 filing for a new indication; we did not count that record as an alternative. FDA's National Drug Code directory gives the remaining Byetta listings marketing end dates of Nov. 30 and Dec. 31, 2026, and Amneal's listings end dates of May 31 and June 30, 2027. Patients still on exenatide will likely need another agent within months.

Inhaled ribavirin is the second. Both Virazole and the one approved generic, from Chartwell, are marked discontinued. The NDC directory still carries a 6 g ribavirin inhalation listing under the Virazole application from Oceanside Pharmaceuticals, so hospital pharmacies that keep it on formulary should confirm their own supply. The third gap is narrower: etoposide capsules remain available at 50 mg, from Vepesid's maker and from Mylan, so a 100 mg dose can still be given as two capsules.

Dibenzyline itself had been flagged for months. FDA's drug shortage data lists its packages as "To Be Discontinued" in an entry updated Dec. 1, 2025. Five generic phenoxybenzamine capsules are listed as marketed.

What should practices do?

Run the 17 names against your active medication lists, starting with exenatide, which has a real deadline in the NDC end dates. Some brand-only prescriptions written as "dispense as written" will now fail at the pharmacy, and prior authorization approvals tied to a brand name may need to be redone for the generic. For drugs in short supply generally, a listed product and an available product are not the same thing, as the stimulant shortage listings show. Patients moving off exenatide will land on other GLP-1 drugs, where a new CDC survey found two in five users changed how they took them in 2025, so plan the switch with the dose the patient can afford to keep taking.

Share this storyImages sized for Facebook, Instagram, TikTok, X and link previews

Download all imagesCopy link

This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.